Education
About Us
Working with TipRanks
Follow Us
CANC - ETF AI Analysis
Top Page
Tema Oncology ETF (CANC)
Rating:62Neutral
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has shown strong gains over the past three months and solid year-to-date results, indicating positive recent momentum.
Leading Oncology and Pharma Holdings
Many of the top holdings, including several major pharmaceutical and biotech names, have delivered generally strong or steady performance, helping support the fund’s returns.
Global Oncology Exposure
While most assets are in U.S. companies, the fund also holds meaningful positions in Switzerland, the UK, and Japan, adding some international diversification within oncology.
Negative Factors
High Sector Concentration
With almost all assets in the health care sector and focused specifically on oncology, the fund is heavily exposed to swings in one industry.
Relatively High Expense Ratio
The fund’s expense ratio is on the higher side for an ETF, which can eat into long-term returns compared with lower-cost options.
Dependence on a Narrow Theme
Because the ETF targets a single medical specialty, its performance is closely tied to the success and sentiment of oncology-related companies rather than the broader market.
CANC vs. SPDR S&P 500 ETF (SPY)
AUM158.18M
RegionGlobal
Expense Ratio0.75%
Beta0.81
IssuerTema
Inception DateAug 15, 2023
Dividend Yield0.05%
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume26,043
30 Day Avg. Volume37,873
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
50.19Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering57
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
CANC Summary
The Tema Oncology ETF (CANC) is a health care fund focused specifically on cancer-related companies, mainly in the pharma, biotech, and life sciences areas. It does not track a traditional index, but instead selects firms working on cancer drugs and treatments. Well-known holdings include Eli Lilly and Merck, along with other global cancer research leaders. Someone might invest in this ETF to seek long-term growth from advances in cancer therapies while getting diversification across many oncology companies. A key risk is that it is heavily concentrated in one sector, so its price can swing sharply with news and trends in cancer drug development.
How much will it cost me?The Tema Oncology ETF has an expense ratio of 0.75%, which means you’ll pay $7.50 per year for every $1,000 invested. This is higher than average because the fund is actively managed, focusing on a specialized niche in the health care sector that requires expert research and selection of companies.
What would affect this ETF?The Tema Oncology ETF could benefit from advancements in cancer research and increased global demand for innovative treatments, as well as strong performance from top holdings like Eli Lilly and Roche, which are leaders in oncology. However, it may face challenges from regulatory hurdles, high development costs in the biotech sector, and potential economic downturns that could impact funding for healthcare innovation.
CANC Top 10 Holdings
This oncology-focused ETF is essentially a bet on cancer drugs, with nearly all its firepower in global pharma and biotech names. Established giants like Novartis, AstraZeneca, Merck, Roche, and Bristol-Myers are doing the heavy lifting, with their shares generally rising and providing a steadier backbone for the fund. On the flip side, more speculative biotech names such as Revolution Medicines, BridgeBio, Nuvalent, and Cogent Biosciences have been lagging or choppy, adding volatility. Overall, it’s a globally diversified cancer play, but with real concentration in a handful of big drugmakers and risky up-and-comers.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Revolution Medicines | 5.93% | $9.44M | $19.78B | 171.02% | 52 Neutral | |
| Novartis AG | 4.49% | $7.15M | CHF238.47B | 21.58% | 80 Outperform | |
| AstraZeneca | 4.40% | $7.00M | $300.78B | 21.96% | 80 Outperform | |
| Roche Holding | 4.33% | $6.90M | $342.20B | 28.63% | 74 Outperform | |
| Eli Lilly & Co | 4.17% | $6.64M | $951.27B | 21.53% | 72 Outperform | |
| Bristol-Myers Squibb | 3.60% | $5.73M | $123.47B | -3.93% | 78 Outperform | |
| Arcellx Inc | 3.55% | $5.64M | $6.70B | 58.76% | 40 Underperform | |
| BridgeBio Pharma | 3.54% | $5.64M | $12.73B | 108.15% | 59 Neutral | |
| Merck & Company | 3.39% | $5.39M | $289.54B | 22.98% | 80 Outperform | |
| Cogent Biosciences | 3.22% | $5.13M | $6.01B | 428.96% | 37 Underperform |
CANC Technical Analysis
Positive
―
Price Trends
36.42
Positive
34.66
Positive
30.51
Positive
Market Momentum
0.21
Positive
52.17
Neutral
32.19
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For CANC, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 37.06, equal to the 50-day MA of 36.42, and equal to the 200-day MA of 30.51, indicating a bullish trend. The MACD of 0.21 indicates Positive momentum. The RSI at 52.17 is Neutral, neither overbought nor oversold. The STOCH value of 32.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CANC.
CANC Peer Comparison
Comparison Results
Performance Comparison
CANC
Tema Oncology ETF
37.09
12.37
50.04%
AVRE
Avantis Real Estate ETF
―
―
―
BKGI
BNY Mellon Global Infrastructure Income ETF
―
―
―
ARKX
ARK Space Exploration & Innovation ETF
―
―
―
MGNR
American Beacon GLG Natural Resources ETF
―
―
―
EIPX
FT Energy Income Partners Strategy ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents